FOX Translator
No data currently available.
No data currently available.
You know that buying a stock makes you part owner of a company, theoretically with millions of other people. But, while ownership has its privileges (at minimum you get a neat stock certificate and an invitation to the annual meeting), being an owner doesn't necessarily pay. Sure, you make money if the stock goes up, but only if you sell, and you can, in theory, lose all the value of your investment if the stock tanks.
Enter the dividend. Here, you get money simply from holding the stock. Companies pay a yield, which is expressed in a percentage based on the stock's price. For example, if a stock trades at $10, and pays a 10% annual yield, your dividend payment would be a $1. (Usually, companies break out the payments quarterly, so, using our example, you¿d get, well, a quarter each quarter.)
Companies that pay dividends fall into a few categories. First, you've got your big, stable companies that generate enough cash that it makes sense to throw some back to shareholders. Next, there are businesses, like real estate investment trusts, that are in the business of sitting back and receiving cash, then distributing it to holders. And, then there are companies that need to dangle a high dividend yield like a carrot to ease investor fears. Cigarette-maker Altria has been doing this for years.
Simply because a company pays a dividend doesn't make it a good investment. After all, you may want to take a chance on a growth stock that can move higher in price than dividend payers are known to do. But, you can¿t beat the safety of knowing that, even if a stock doesn't move in a year, you¿re at least making something off your investment.
Home
Tuesday, July 22, 2008
Thirty Years After First Test Tube Baby, Scientists Pursue Healthier Human Embryo
Comtex
LEXINGTON, Mass., July 22, 2008 /PRNewswire via COMTEX/ ----On the 30th anniversary of the birth of the world's first "test tube baby," Louise Brown of England, embryologists at one of the nation's largest in vitro fertilization (IVF) clinics are conducting a clinical study aimed at the pursuit of a healthier human embryo with dramatically increased chances of full gestation to birth of a healthy baby.
This month the Reproductive Science Center of New England partners with Molecular Biometrics, a privately-held company developing diagnostic tools to characterize biologic function in health and disease, to begin a clinical study of a process known as metabolomic profiling, an advanced means of assessing embryo viability.
Success of the study may hold out hope that doctors can succeed in identifying a single embryo with excellent chances of a full pregnancy. Due to a multitude of chromosomal abnormalities which exist in most embryos, a significant number of embryos do not implant successfully. Many others spontaneously miscarry very soon following implantation, as occurs frequently in cases of naturally conceived pregnancies.
Traditionally, in vitro fertilization (IVF) specialists have improved the odds by transferring more than one embryo to a woman's uterus, a practice that doctors are moving away from because it increases the chances of high-order multiple births and accompanying health risks to both mother and child.
"Ideally, by improving the process of embryo selection, we can reduce multiple births and optimize birth outcomes," said Dr. Kathryn Go, laboratory director of RSC New England.
To learn more, please visit http://www.rscnewengland.com.
About RSC New England
With 11 locations throughout New England, Reproductive Science Center is the seventh largest medical practice of its kind nationwide, known coast to coast for its innovative patient care, advanced laboratory capabilities and for success rates that are among the highest in the U.S. Founded in 1988, RSC is led today by a team of six physicians -- four of whom are women, making it one of the largest groups of female reproductive endocrinologists in the Northeast. RSC is a member of IntegraMed, a national network of 32 fertility centers in 104 locations across the U.S., including 185 physicians and Ph.D. scientists. Nearly one of every four IVF procedures in the U.S. are performed in an IntegraMed fertility practice. For more information, visit http://www.rscnewengland.com.
SOURCE RSC New England
http://www.rscnewengland.com
Copyright (C) 2008 PR Newswire. All rights reserved
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
